Blog

Generic labeling induces doctors to practice patented method of treating subset of patients enrolled in pivotal clinical trial.

October 29, 2017

PTAB provides roadmap for rebutting routine optimization rejections.

September 25, 2017

Generic did not infringe formulation patent under doctrine of equivalents because it used an ingredient that patentee disclosed but did not claim.

September 18, 2017

Claimed pharmacokinetics of chewable tablet were inherent result of practicing the prior art.

August 21, 2017

Trial court applied wrong legal framework to claimed new compound formed during lyophilization.

August 08, 2017

Board gives pointers on how to overcome obviousness rejection over broad prior art disclosure.

July 11, 2017

Court finds Meda Pharmaceuticals’ delay asserting certificate of correction precludes adding the corrected claim to the lawsuit.

June 20, 2017

Horizon’s formulation patent for Pennsaid® survives validity challenge and prevents generic entry in spite of narrow breadth.

June 05, 2017

Mylan's patent on the purity of isosulfan blue, a drug used by oncologists to map lymphatic drainage, was affirmed by the Federal Circuit earlier this month.

May 30, 2017

Arguments that CHO host cells were considered unsuitable for commercial scale manufacturing unavailing because commercial scale was not a limitation in the claims.

May 16, 2017